298 related articles for article (PubMed ID: 28627678)
1. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
Masuda C; Yanagisawa M; Yorozu K; Kurasawa M; Furugaki K; Ishikura N; Iwai T; Sugimoto M; Yamamoto K
Int J Oncol; 2017 Aug; 51(2):425-434. PubMed ID: 28627678
[TBL] [Abstract][Full Text] [Related]
2. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
[TBL] [Abstract][Full Text] [Related]
3. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
4. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
7. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
Li H; Takayama K; Wang S; Shiraishi Y; Gotanda K; Harada T; Furuyama K; Iwama E; Ieiri I; Okamoto I; Nakanishi Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1297-305. PubMed ID: 25344762
[TBL] [Abstract][Full Text] [Related]
8. MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.
Nishidate M; Yamamoto K; Masuda C; Aikawa H; Hayashi M; Kawanishi T; Hamada A
Sci Rep; 2017 Dec; 7(1):16763. PubMed ID: 29196706
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
[TBL] [Abstract][Full Text] [Related]
10. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
11. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
Gautschi O; Mach N; Rothschild SI; Li Q; Stahel RA; Zippelius A; Cathomas R; Früh M; Betticher DC; Peters S; Rauch D; Feilchenfeldt J; Bubendorf L; Savic S; Jaggi R; Leibundgut EO; Largiadèr C; Brutsche M; Pilop C; Stalder L; Pless M; Ochsenbein AF;
Clin Lung Cancer; 2015 Sep; 16(5):358-65. PubMed ID: 25843489
[TBL] [Abstract][Full Text] [Related]
13. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
14. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H
Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Zhou Q; Xu CR; Cheng Y; Liu YP; Chen GY; Cui JW; Yang N; Song Y; Li XL; Lu S; Zhou JY; Ma ZY; Yu SY; Huang C; Shu YQ; Wang Z; Yang JJ; Tu HY; Zhong WZ; Wu YL
Cancer Cell; 2021 Sep; 39(9):1279-1291.e3. PubMed ID: 34388377
[TBL] [Abstract][Full Text] [Related]
16. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
17. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
[TBL] [Abstract][Full Text] [Related]
18. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.
Kato T; Seto T; Nishio M; Goto K; Yamamoto N; Okamoto I; Tao L; Yu W; Khaznadar T; Tajima K; Shibata M; Seki A; Yamamoto N
Drug Saf; 2018 Feb; 41(2):229-237. PubMed ID: 29043496
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
Yamamoto N; Seto T; Nishio M; Goto K; Yamamoto N; Okamoto I; Yamanaka T; Tanaka M; Takahashi K; Fukuoka M
Lung Cancer; 2021 Jan; 151():20-24. PubMed ID: 33279874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]